Tempus AI
24
12
17
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
8.3%
2 terminated/withdrawn out of 24 trials
66.7%
-19.9% vs industry average
8%
2 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
Role: lead
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
Role: collaborator
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Role: lead
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Role: lead
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Role: collaborator
Umbrella Study for Analysis of Data Related to Patients With Cancer
Role: lead
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
Role: lead
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Role: lead
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Role: lead
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Role: collaborator
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Role: collaborator
Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform
Role: lead
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Role: lead
GEMINI-NSCLC: NSCLC Biomarker Study
Role: lead
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Role: lead
Liquid BiOpsy, Lung and Colon Cancer in AndaluciA
Role: collaborator
PRediction Of Glycemic RESponse Study
Role: collaborator
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Role: lead
Tempus Priority Study: A Pan-tumor Observational Study
Role: lead
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Role: collaborator